Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQS7 | ISIN: US65488A1016 | Ticker-Symbol:
NASDAQ
04.03.25 | 21:59
0,190 US-Dollar
-0,52 % -0,001
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NKGEN BIOTECH INC Chart 1 Jahr
5-Tage-Chart
NKGEN BIOTECH INC 5-Tage-Chart

Aktuelle News zur NKGEN BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
NKGEN BIOTECH Aktie jetzt für 0€ handeln
20.05.NKGen Biotech, Inc. - 8-K, Current Report1
08.05.NKGen CEO puts skin in the game, investing $2.6M to move biotech toward Alzheimer's readout8
08.05.NKGen Biotech, Inc.: NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations76New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed...
► Artikel lesen
08.05.NKGen Biotech, Inc. - 8-K, Current Report-
07.05.NKGen Biotech, Inc.: NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting2
22.04.NKGen Biotech, Inc. - 8-K, Current Report1
31.03.NKGen Biotech, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4054
13.03.NKGen Biotech, Inc.: NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit1
11.03.NKGen Biotech, Inc. - 8-K, Current Report3
04.03.NKGen Biotech wechselt nach Nasdaq-Delisting zum OTC-Markt6
04.03.NKGen Biotech shifts to OTC Markets after Nasdaq delisting5
04.03.NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented362Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol "NKGN" for common stock and "NKGNW" for warrants.NKGen Biotech, Inc. ("NKGen" or the "Company")...
► Artikel lesen
04.03.NKGen Biotech, Inc. - 10-Q, Quarterly Report-
25.02.NKGen Biotech, Inc. - 8-K, Current Report1
21.02.NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program169SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization...
► Artikel lesen
19.02.NKGen Biotech: NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site3
02.01.NKGen Biotech, Inc. - 8-K, Current Report1
12.12.24NKGen Biotech, Inc. - 8-K, Current Report-
26.11.24NKGen Biotech, Inc.: NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel169SANTA ANA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), today announced it received a notice (the "Notice") on November 20, 2024 from the...
► Artikel lesen
12.09.24NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial152Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found to have improved CDR-SB cognitive scores...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1